These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36284319)

  • 1. Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region.
    Resta E; Scioscia G; Lacedonia D; Quarato CMI; Panza F; Resta O; Lepore G; Buonamico E; Di Lecce V; Carpagnano GE; Barbaro MPF; Rossi N
    BMC Health Serv Res; 2022 Oct; 22(1):1283. PubMed ID: 36284319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England.
    Rothnie KJ; Joksaite S; Sansbury LB; Compton C; Di Boscio V; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1455-1466. PubMed ID: 35769225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
    Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain.
    Alcázar-Navarrete B; Jamart L; Sánchez-Covisa J; Juárez M; Graefenhain R; Sicras-Mainar A
    Chest; 2022 Nov; 162(5):1017-1029. PubMed ID: 35787391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β
    Requena G; Banks V; Czira A; Wood R; Tritton T; Wild R; Compton C; Duarte M; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1781-1795. PubMed ID: 35983168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study.
    Mannino D; Bogart M; Wu B; Germain G; Laliberté F; MacKnight SD; Jung Y; Stiegler M; Duh MS
    Respir Med; 2022 Jun; 197():106807. PubMed ID: 35429764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
    Oba Y; Keeney E; Ghatehorde N; Dias S
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β
    Requena G; Banks V; Czira A; Wood R; Tritton T; Wild R; Compton C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():231-245. PubMed ID: 36908830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
    Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
    Marín JM; Mateos L; Roldán J; Echave-Sustaeta JM; Pascual-Guardia S; Pardo MV; Velasco B; Jones CE; Kilbride S; Lipson DA
    Ther Adv Respir Dis; 2020; 14():1753466620963021. PubMed ID: 33121372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD.
    Cazzola M; Rogliani P; Calzetta L; Ora J; Matera MG
    Expert Rev Clin Pharmacol; 2022 Mar; 15(3):269-283. PubMed ID: 35475762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
    Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
    Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
    Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
    Bourdin A; Molinari N; Ferguson GT; Singh B; Siddiqui MK; Holmgren U; Ouwens M; Jenkins M; De Nigris E
    Adv Ther; 2021 Jun; 38(6):3089-3112. PubMed ID: 33929661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
    Kew KM; Dias S; Cates CJ
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
    Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.